Drug
Rogaratinib clinical trials
Also written BAY1163877.
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Bayer (8) · National Cancer Institute (NCI) (1) · Swiss Group for Clinical Cancer Research (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Rogaratinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04595747Written as Rogaratinib
- Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaCompletedPhase 1BayerNCT03473756Written as Rogaratinib (BAY1163877)
- Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedPhase 2Swiss Group for Clinical Cancer ResearchNCT03762122Written as Rogaratinib
- Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial CarcinomaCompletedPhase 2/3BayerNCT03410693Written as Rogaratinib (BAY1163877)
- Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsCompletedPhase 1BayerNCT03517956Written as Rogaratinib (BAY1163877)
- Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedPhase 2BayerNCT04125693Written as Rogaratinib (BAY1163877)
- Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)CompletedPhase 1BayerNCT01976741Written as Rogaratinib (BAY1163877) oral solution
- Rogaratinib (BAY1163877) in Chinese PatientsCompletedPhase 1BayerNCT03788603Written as Rogaratinib (BAY1163877)
- Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionWithdrawnPhase 2Dana-Farber Cancer InstituteNCT04040725Written as Rogaratinib
- Rogaratinib (BAY1163877) Human Mass Balance StudyCompletedPhase 1BayerNCT03484585Written as Rogaratinib (BAY1163877)
- Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid TumorsCompletedPhase 1BayerNCT02592785Written as BAY1163877
Codes
What other systems call Rogaratinib · ClinicalTrials.gg INT001062
- MeSH (NLM) C000630155RogaratinibOne source NLM
- UNII (FDA) 98BSN6N516ROGARATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27272111rogaratinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C112205RogaratinibOne source FDA
- DrugBank DB15078One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630155 | Rogaratinib | One source NLM |
| UNII (FDA) | 98BSN6N516 | ROGARATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27272111 | rogaratinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C112205 | Rogaratinib | One source FDA |
| DrugBank | DB15078 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.